Vivaldi Biosciences
Phase 2Developing nasal-spray, self-adjuvanting vaccines for viral respiratory diseases based on our Delta NS1 technology platform: DeltaFLU: Universal Influenza Vaccine in Phase 2 clinical development for broad protection against all strains of influenza. Delta-19: Covid-19 + Universal Influenza combin
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Funding information not available
About
Developing nasal-spray, self-adjuvanting vaccines for viral respiratory diseases based on our Delta NS1 technology platform: DeltaFLU: Universal Influenza Vaccine in Phase 2 clinical development for broad protection against all strains of influenza. Delta-19: Covid-19 + Universal Influenza combin
Vaccines